A randomized phase II/III trial of conventional paclitaxel and carboplatin with/without bevacizumab versus dose-dense paclitaxel and carboplatin with/without bevacizumab, in stage IVB, recurrent, or persistent cervical carcinoma (JCOG1311): Results of the phase II part.

被引：0

作者：

Ishikawa, Mitsuya

Kitagawa, Ryo

Shibata, Taro

Tokunaga, Hideki

Iwata, Takashi

Nishio, Shin

Takada, Toshio

Mori, Masahiko

Horie, Koji

Kudaka, Wataru

Kagabu, Masahiro

Tanikawa, Michihiro

Kobayashi, Hiroaki

Yaegashi, Nobuo

机构：

[1] Natl Canc Ctr, Dept Gynecol, Tokyo, Japan

[2] Moriya Daiichi Gen Hosp, Dept Gynecol & Obstet, Ibaraki, Japan

[3] Natl Canc Ctr, Operat Off, Japan Clin Oncol Grp Data Ctr, Tokyo, Japan

[4] Tohoku Univ Hosp, Dept Gynecol, Sendai, Miyagi, Japan

[5] Keio Univ, Dept Obstet & Gynecol, Sch Med, Tokyo, Japan

[6] Kurume Univ, Dept Obstet & Gynecol, Sch Med, Kurume, Fukuoka, Japan

[7] Kitasato Univ, Dept Obstet & Gynecol, Sch Med, Sagamihara, Kanagawa, Japan

[8] Aichi Canc Ctr Hosp, Dept Gynecol Oncol, Nagoya, Aichi, Japan

[9] Saitama Canc Ctr, Dept Gynecol, Saitama, Japan

[10] Univ Ryukyus, Grad Sch Med Sci, Dept Obstet & Gynecol, Nishihara, Okinawa, Japan

[11] Iwate Med Univ, Dept Obstet & Gynecol, Sch Med, Morioka, Iwate, Japan

[12] Univ Tokyo, Dept Obstet & Gynecol, Tokyo, Japan

[13] Kagoshima Univ, Fac Med, Dept Obstet & Gynecol, Kagoshima, Japan

[14] Tohoku Univ, Dept Obstet & Gynecol, Grad Sch Med, Sendai, Miyagi, Japan

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

6027

引用

页数：2

共 50 条

[41] A randomized phase II trial of bevacizumab vs. bevacizumab and erlotinib as first-line consolidation after carboplatin, paclitaxel, and bevacizumab in newly diagnosed patients with mullerian tumors
Susana Campos
Ursula Matulonis
Suzanne Berlin
Neil Horowitz
Joyce Liu
Carolyn Krasner
Lee Hang
Corrine Zarwan
William Barry
Tina Colella
Christen Whalen
Melina Shoni
Christine Lundquist
Michael J. Birrer
Richard Penson
International Journal of Clinical Oncology, 2022, 27 : 1881 - 1890
[42] Phase II Trial of Bevacizumab Plus Weekly Paclitaxel, Carboplatin, and Metronomic Cyclophosphamide With or Without Trastuzumab and Endocrine Therapy as Preoperative Treatment of Inflammatory Breast Cancer
Palazzo, Antonella
Dellapasqua, Silvia
Munzone, Elisabetta
Bagnardi, Vincenzo
Mazza, Manuelita
Cancello, Giuseppe
Ghisini, Raffaella
Iorfida, Monica
Montagna, Emilia
Goldhirsch, Aaron
Colleoni, Marco
CLINICAL BREAST CANCER, 2018, 18 (04) : 328 - 335
[43] Quality-of-life outcomes from a randomized phase III trial of dose-dense weekly paclitaxel and carboplatin compared with conventional paclitaxel and carboplatin as a first-line treatment for stage II-IV ovarian cancer: Japanese Gynecologic Oncology Group Trial (JGOG3016)
Harano, K.
Terauchi, F.
Katsumata, N.
Takahashi, F.
Yasuda, M.
Takakura, S.
Takano, M.
Yamamoto, Y.
Sugiyama, T.
ANNALS OF ONCOLOGY, 2014, 25 (01) : 251 - 257
[44] Phase II trial of dose-dense doxorubicin plus gemcitabine followed by paclitaxel plus carboplatin in patients with advanced urothelial carcinoma and impaired renal function
Galsky, Matthew D.
Iasonos, Alexia
Mironov, Svetlana
Scattergood, Joseph
Boyle, Mary G.
Bajorin, Dean F.
CANCER, 2007, 109 (03) : 549 - 555
[45] S1701: A randomized phase II trial of carboplatin-paclitaxel with and without ramucirumab in patients with locally advanced, recurrent, or metastatic thymic carcinoma.
Tsao, Anne S.
Hsieh, Ming-Hui
Koczywas, Marianna
Tu, Janet Chen
Riess, Jonathan W.
Tanvetyanon, Tawee
Ma, Barbara Ting-Wen
Zhao, Yingqi
Redman, Mary Weber
Edelman, Martin Joseph
Gandara, David R.
Kelly, Karen
Gray, Jhanelle E.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[46] BEVACIZUMAB COMBINED WITH FIRST-LINE CARBOPLATIN AND PACLITAXEL FOR METASTATIC/RECURRENT/PERSISTENT CERVICAL CANCER: PRIMARY RESULTS FROM THE GLOBAL SINGLE-ARM PHASE II CECILIA STUDY
Colombo, N.
Dreosti, L.
McCormack, M.
Nogueira-Rodrigues, A.
Scambia, G.
Roszak, A.
Donica, M.
Ulker, B.
Gonzalez-Martin, A.
Redondo, A.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2019, 29 : A22 - A23
[47] Bevacizumab versus placebo in combination with paclitaxel and carboplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase II trial
Zhou, T.
Yang, Y.
Ma, S.
Lin, L.
Zhou, T.
Zhang, C.
Ding, X.
Wang, R.
Feng, G.
Chen, Y.
Xu, R.
Huang, Y.
Zhang, L.
ESMO OPEN, 2021, 6 (06)
[48] A Randomized, Phase III Study Comparing Carboplatin/Paclitaxel or Carboplatin/Paclitaxel/Bevacizumab with or without Concurrent Cetuximab in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC): SWOG S0819
Herbst, Roy
Redman, Mary
Kim, Edward S.
Semrad, Thomas J.
Bazhenova, Lyudmila
Masters, Gregory
Oettel, Kurt
Guaglianone, Perry
Reynolds, Christopher
Karnad, Anand
Arnold, Susanne M.
Varella-Garcia, Marileila
Moon, James
Mack, Philip C.
Blanke, Charles D.
Hirsch, Fred R.
Gandara, David R.
JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S795 - S795
[49] RESULTS OF A RANDOMIZED PHASE II TRIAL OF PACLITAXEL AND CARBOPLATIN VERSUS BLEOMYCIN, ETOPOSIDE AND CISPLATIN FOR NEWLY DIAGNOSED AND RECURRENT CHEMONAIVE STROMAL OVARIAN TUMORS
Brown, J.
Miller, A.
Moxley, K.
Backes, F.
Nagel, C.
Bender, D.
Miller, D.
Powell, M.
Westin, S.
Bonebrake, A.
Muller, C.
Secord, A. Alvarez
Crane, E.
Schorge, J.
Tew, W.
Sood, A.
Aghajanian, C.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2020, 30 : A56 - A56
[50] Primary results from CECILIA, a global single-arm phase II study evaluating bevacizumab, carboplatin and paclitaxel for advanced cervical cancer
Redondo, Andres
Colombo, Nicoletta
McCormack, Mary
Dreosti, Lydia
Nogueira-Rodrigues, Angelica
Scambia, Giovanni
Lorusso, Domenica
Joly, Florence
Schenker, Michael
Ruff, Paul
Estevez-Diz, Maria
Irahara, Natsumi
Donica, Margarita
Gonzalez-Martin, Antonio
GYNECOLOGIC ONCOLOGY, 2020, 159 (01) : 142 - 149

← 1 2 3 4 5 →